Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

Cancer Cell

Volumn 31, Issue 4, 2017, Pages 501-515.e8

  Seaman, Steven ^a   Zhu, Zhongyu ^a   Saha, Saurabh ^b   Zhang, Xiaoyan M ^b   Yang, Mi Young ^a   Hilton, Mary Beth ^a,c   Morris, Karen ^a,c   Szot, Christopher ^a   Morris, Holly ^a   Swing, Deborah A ^a   Tessarollo, Lino ^a   Smith, Sean W ^d   Degrado, Sylvia ^d   Borkin, Dmitry ^d   Jain, Nareshkumar ^d   Scheiermann, Julia ^a   Feng, Yang ^a   Wang, Yanping ^a   Li, Jinyu ^a   Welsch, Dean ^b   DeCrescenzo, Gary ^b   Chaudhary, Amit ^a   Zudaire, Enrique ^a   Klarmann, Kimberly D ^a,c   Keller, Jonathan R ^a,c   Dimitrov, Dimiter S ^a   St Croix, Brad ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b Aventis Pharmaceuticals   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d Antitope Ltd   (United Kingdom)

Author keywords

Abcb1; ADC; angiogenesis; B7H3; cancer; endothelium; P glycoprotein; P gp; PBD; TEM

Indexed keywords

CATHEPSIN B; CD276 B7 H3 PROTEIN; CELL SURFACE PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BENZODIAZEPINE DERIVATIVE; CD276 PROTEIN, HUMAN; CD276 PROTEIN, MOUSE; OLIGOPEPTIDE; PYRROLE DERIVATIVE; PYRROLO(2,1-C)(1,4)BENZODIAZEPINE; VEDOTIN;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CROSS REACTION; DISEASE ERADICATION; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GLIOMA; HEART CANCER; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MELANOMA; MESOTHELIOMA; MOUSE; MUSCLE CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CANCER; ANIMAL; BLOOD VESSEL; C57BL MOUSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; RABBITS AND HARES; TRANSGENIC MOUSE; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; B7 ANTIGENS; BENZODIAZEPINES; BLOOD VESSELS; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGOPEPTIDES; PYRROLES; RABBITS;

EID: 85017339129     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.03.005     Document Type: Article

References (41)

1. Abdollahi, A., Folkman, J., Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat. 13 (2010), 16–28.
2. Ahmed, M., Cheng, M., Zhao, Q., Goldgur, Y., Cheal, S.M., Guo, H.F., Larson, S.M., Cheung, N.K., Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J. Biol. Chem. 290 (2015), 30018–30029.
3. Akiyama, K., Ohga, N., Hida, Y., Kawamoto, T., Sadamoto, Y., Ishikawa, S., Maishi, N., Akino, T., Kondoh, M., Matsuda, A., et al. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am. J. Pathol. 180 (2012), 1283–1293.
4. Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A., Giuliano, A.E., Hoon, D.S., B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann. Surg. 252 (2010), 1044–1051.
5. Baskin, J.M., Prescher, J.A., Laughlin, S.T., Agard, N.J., Chang, P.V., Miller, I.A., Lo, A., Codelli, J.A., Bertozzi, C.R., Copper-free click chemistry for dynamic in vivo imaging. Proc. Natl. Acad. Sci. USA 104 (2007), 16793–16797.
6. Bridgeman, V.L., Vermeulen, P.B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M.R., Wan, E., Frentzas, S., Schweiger, T., et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol. 241 (2016), 362–374.
7. Brunner, A., Hinterholzer, S., Riss, P., Heinze, G., Brustmann, H., Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol. Oncol. 124 (2012), 105–111.
8. Chapoval, A.I., Ni, J., Lau, J.S., Wilcox, R.A., Flies, D.B., Liu, D., Dong, H., Sica, G.L., Zhu, G., Tamada, K., Chen, L., B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2 (2001), 269–274.
9. Cheang, M.C., Treaba, D.O., Speers, C.H., Olivotto, I.A., Bajdik, C.D., Chia, S.K., Goldstein, L.C., Gelmon, K.A., Huntsman, D., Gilks, C.B., et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J. Clin. Oncol. 24 (2006), 5637–5644.
10. Chen, R., Hou, J., Newman, E., Kim, Y., Donohue, C., Liu, X., Thomas, S.H., Forman, S.J., Kane, S.E., CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol. Cancer Ther. 14 (2015), 1376–1384.
11. Dorywalska, M., Dushin, R., Moine, L., Farias, S.E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M.G., Tran, T.T., et al. Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design. Mol. Cancer Ther. 15 (2016), 958–970.
12. Elinzano, H., Hebda, N., Luppe, D., Turchetti, W., Rosati, K., Sikov, W.M., Safran, H., PSMA ADC for progressive glioblastoma: phase II Brown University Oncology Research Group Study. J. Clin. Oncol., 34(suppl), 2016 abstract 2065.
13. Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971), 1182–1186.
14. Gerber, H.P., Senter, P.D., Grewal, I.S., Antibody drug-conjugates targeting the tumor vasculature: current and future developments. MAbs 1 (2009), 247–253.
15. Hartley, J.A., The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin. Investig. Drugs 20 (2011), 733–744.
16. Huang, X., Bennett, M., Thorpe, P.E., Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 61 (2004), 1–11.
17. Jat, P.S., Noble, M.D., Ataliotis, P., Tanaka, Y., Yannoutsos, N., Larsen, L., Kioussis, D., Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc. Natl. Acad. Sci. USA 88 (1991), 5096–5100.
18. Jeffrey, S.C., Burke, P.J., Lyon, R.P., Meyer, D.W., Sussman, D., Anderson, M., Hunter, J.H., Leiske, C.I., Miyamoto, J.B., Nicholas, N.D., et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug. Chem. 24 (2013), 1256–1263.
19. Kerbel, R.S., Tumor angiogenesis. N. Engl. J. Med. 358 (2008), 2039–2049.
20. Kim, E.G., Kim, K.M., Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomol. Ther. (Seoul) 23 (2015), 493–509.
21. Kuczynski, E.A., Yin, M., Bar-Zion, A., Lee, C.R., Butz, H., Man, S., Daley, F., Vermeulen, P.B., Yousef, G.M., Foster, F.S., et al. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J. Natl. Cancer Inst., 108, 2016, djw030, 10.1093/jnci/djw030.
22. Kung Sutherland, M.S., Walter, R.B., Jeffrey, S.C., Burke, P.J., Yu, C., Kostner, H., Stone, I., Ryan, M.C., Sussman, D., Lyon, R.P., et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122 (2013), 1455–1463.
23. Li, F., Emmerton, K.K., Jonas, M., Zhang, X., Miyamoto, J.B., Setter, J.R., Nicholas, N.D., Okeley, N.M., Lyon, R.P., Benjamin, D.R., Law, C.L., Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 76 (2016), 2710–2719.
24. Loo, D., Alderson, R.F., Chen, F.Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 18 (2012), 3834–3845.
25. Loos, M., Hedderich, D.M., Friess, H., Kleeff, J., B7-h3 and its role in antitumor immunity. Clin. Dev. Immunol., 2010, 2010, 683875.
26. Modak, S., Kramer, K., Gultekin, S.H., Guo, H.F., Cheung, N.K., Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 61 (2001), 4048–4054.
27. Nomura, N., Pastorino, S., Jiang, P., Lambert, G., Crawford, J.R., Gymnopoulos, M., Piccioni, D., Juarez, T., Pingle, S.C., Makale, M., Kesari, S., Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int., 14, 2014, 26.
28. Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K.M., Carver, L.A., Testa, J.E., Schnitzer, J.E., Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429 (2004), 629–635.
29. Olson, W.C., Israel, R.J., Antibody-drug conjugates targeting prostate-specific membrane antigen. Front Biosci. (Landmark Ed) 19 (2014), 12–33.
30. Qin, X., Zhang, H., Ye, D., Dai, B., Zhu, Y., Shi, G., B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma. Onco Targets Ther. 6 (2013), 1667–1673.
31. Seaman, S., Stevens, J., Yang, M.Y., Logsdon, D., Graff-Cherry, C., St Croix, B., Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11 (2007), 539–554.
32. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K.E., Montgomery, E., Lal, A., Riggins, G.J., Lengauer, C., Vogelstein, B., Kinzler, K.W., Genes expressed in human tumor endothelium. Science 289 (2000), 1197–1202.
33. Suh, W.K., Gajewska, B.U., Okada, H., Gronski, M.A., Bertram, E.M., Dawicki, W., Duncan, G.S., Bukczynski, J., Plyte, S., Elia, A., et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4 (2003), 899–906.
34. Visintin, A., Knowlton, K., Tyminski, E., Lin, C.I., Zheng, X., Marquette, K., Jain, S., Tchistiakova, L., Li, D., O'Donnell, C.J., et al. Novel anti-TM4SF1 antibody-drug conjugates with activity against tumor cells and tumor vasculature. Mol. Cancer Ther. 14 (2015), 1868–1876.
35. Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15 (2015), 361–370.
36. Xiao, L., Harrell, J.C., Perou, C.M., Dudley, A.C., Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro. Angiogenesis 17 (2014), 511–518.
37. Xu, L., Stevens, J., Hilton, M.B., Seaman, S., Conrads, T.P., Veenstra, T.D., Logsdon, D., Morris, H., Swing, D.A., Patel, N.L., et al. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci. Transl Med., 6, 2014, 242ra284.
38. Yu, S.F., Zheng, B., Go, M., Lau, J., Spencer, S., Raab, H., Soriano, R., Jhunjhunwala, S., Cohen, R., Caruso, M., et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin. Cancer Res. 21 (2015), 3298–3306.
39. Zang, X., Sullivan, P.S., Soslow, R.A., Waitz, R., Reuter, V.E., Wilton, A., Thaler, H.T., Arul, M., Slovin, S.F., Wei, J., et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod. Pathol. 23 (2010), 1104–1112.
40. Zhu, Z., Dimitrov, D.S., Construction of a large naive human phage-displayed Fab library through one-step cloning. Methods Mol. Biol. 525 (2009), 129–142 xv.
41. Zhu, Z., Ramakrishnan, B., Li, J., Wang, Y., Feng, Y., Prabakaran, P., Colantonio, S., Dyba, M.A., Qasba, P.K., Dimitrov, D.S., Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs 6 (2014), 1190–1200.